Loading...
Loading...
Stifel Nicolaus raises its rating on Affymax
AFFY to Buy from Hold and establishes a $19 price target on shares as it expects Peginesatide approval on March 27, 2012.
Stifel Nicolaus says, "Affymax is preparing to launch lead drug Peginesatide into the U.S. dialysis market in 2Q. An FDA advisory panel voted almost unanimously for approval in December; we expect marketing approval on or before the March 27 PDUFA date. We expect Peginesatide will be a disruptive force in the market for erythropoietin stimulating agents. Amgen has had monopoly pricing power in this market for over twenty years; Peginesatide offers a long-acting (once/month) product, which we expect will be competitively priced in comparison to Amgen's Epogen."
AFFY closed at $11.22 a share on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in